A
Allogene Therapeutics D
D
ALLO
1.81000
USD
-0.03
(-1.63%)
مغلق
حجم التداول
46,639
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
379,506,485
المقالات
العنوان: Allogene Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research anddevelopment efforts.